(From the November 2014 Issue of MedStat)
For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.
Updated Pyxis Override Lists were APPROVED for IMC-H8B1, IMC-H8B2, PICU-H2B1, and PICU-H2B2.
Clinic medication stock lists for Hilliard Urgent Care and Rheumatology Clinic were APPROVED.
Six-month formulary reviews were presented for the following medications: atovaquone and proguanil (Malarone®) and meningococcal groups A, C, Y and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine (MCV4-CRM) (Menveo®). Both were APPROVED for maintenance on formulary.
An Atypical Antipsychotic Drug Class Review was presented outlining current formulary items (risperidone, quetiapine, aripiprazole, and olanzapine) as well as requested formulary additions. Paliperidone (Invega®) and Clozapine (Clozaril®; FazaClo®) were APPROVED for formulary addition. Initiation of therapy in pediatric patients for psychiatric indications should be limited to prescribing by or in consultation with prescribers from Psychiatry or Developmental Pediatrics which will be guided by Epic alerts. The drug class review will be posted on the P&T intranet website. A review of formulary drug use of both agents will be presented in six months.
Dantrolene (Ryanodex®) was APPROVED for formulary addition for management of malignant hyperthermia. Older formulations of dantrolene will be removed from hospital stock in the coming months. A product conversion announcement will be made at a later date. The abbreviated monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented six months after product conversion.
Follow-up occurred on the status of the LPIP: RN Administration of Ondansetron. The joint Boards of Medicine, Nursing and Pharmacy did not approve ondansetron as meeting the joint board’s definition of an emergency treatment; therefore, implementation of this LPIP will not occur.